Biotech

News

CRISPR gene editing stocks fall after Editas CEO resigns

Shares in firms developing therapies based on CRISPR gene editing technology have fallen after the resignation of the CEO of one of the leading biotechs in the field, Editas.

Events

Partner Content

8th Annual Pharma CI Europe Conference & Exhibition

The Best Assembly of Competitive Intelligence Experts

Events

Partner Content

10th Annual Pharma Market Research Conference

The best industry assembly of market researchers.

R&D

Biotech strategy and nanomedicine: the pharmaphorum podcast

For episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Wellcome Coll

News

WuXi AppTec eyes acquisitions after $1bn Hong Kong IPO

Chinese biotech WuXi AppTec has completed its listing on Hong Kong’s HKEX, raising $967m just months after making its debut on the Shanghai exchange.

News

Pharma companies warned over 'no deal' Brexit disruption

The government is asking pharma companies to introduce additional measures, over and above the stockpiles already in place, in the event of a ‘no-deal’ Brexit.

CRISPR gene editing stocks fall after Editas CEO resigns

8th Annual Pharma CI Europe Conference & Exhibition

10th Annual Pharma Market Research Conference

Biotech strategy and nanomedicine: the pharmaphorum podcast

WuXi AppTec eyes acquisitions after $1bn Hong Kong IPO

Pharma companies warned over 'no deal' Brexit disruption

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Biotech

Editor's Picks